Choice A rationale:
Perineal pad clots are not the greatest risk for this patient. While it’s important to monitor the amount and type of lochia, the nurse’s notes indicate that the patient has a moderate amount of lochia rubra, which is normal within the first few days postpartum. Large clots could indicate a problem such as a retained placental fragment, but this is not mentioned in
the scenario.
Choice B rationale:
Pelvic pain is a common complaint after childbirth due to uterine contractions, especially during breastfeeding, and usually resolves within a few days. The patient’s pain is rated as 4 on a scale of 0 to 10, which is considered moderate. While it’s important to manage the patient’s pain, it’s not the greatest risk in this scenario.
Choice C rationale:
A boggy uterus poses the greatest risk for this patient. A boggy or soft uterus indicates uterine atony, which is a lack of normal muscle tone that can lead to excessive bleeding. This is a serious condition that can lead to postpartum hemorrhage if not treated promptly. The nurse’s notes indicate that the patient’s fundus is boggy and located above the umbilicus, which is a concern. The fundus should be firm and gradually descend into the pelvis within the first few days postpartum.
Choice D rationale:
Breast engorgement is a common discomfort that occurs when the breasts are overly full with milk. It typically occurs within the first week postpartum as the milk supply increases. The nurse’s notes indicate that the patient’s breasts are soft, warm, and tender to touch, which is normal. While it’s important to manage the patient’s comfort, breast
engorgement is not the greatest risk in this scenario.

Choice A rationale

Repaglinide is an oral diabetes medication that helps control blood sugar levels by causing the pancreas to produce insulin. However, it is not typically the first choice for treating gestational diabetes. It is usually used for type 2 diabetes and is not commonly recommended during pregnancy.

Choice B rationale

Glipizide is another oral diabetes medication that works by stimulating the pancreas to produce insulin. Like repaglinide, it is not typically used as a first-line treatment for gestational diabetes and is not commonly recommended during pregnancy.

Choice C rationale

Insulin is the most common treatment for gestational diabetes. It does not cross the placenta and thus does not cause hypoglycemia in the baby. It can be used safely during pregnancy and is effective in controlling blood glucose levels.

Choice D rationale

Acarbose is an alpha-glucosidase inhibitor, which works by slowing the absorption of carbohydrates from the intestine. It is not typically used in pregnancy due to lack of safety data.